ArticleClinical cancer research : an official journal of the American Association for Cancer Research2015
Advancing Clinical Trials to Streamline Drug Development.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Erk5-mediated microglial ferroptosis drives ischemic white matter damage via the Nfatc4-Clptm1l axis.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Integrative multi-omics analysis identifies genetically supported druggable targets for inflammatory bowel disease.Journal, genetic engineering & biotechnology · 2025Article
- Reductive stress and the role of antioxidants in male infertility: a narrative review.Archives of gynecology and obstetrics · 2025Review
- Identification of biomarkers and potential drug targets for esophageal cancer: a Mendelian randomization study.Scientific reports · 2025Article
- Article
- Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?British journal of clinical pharmacology · 2020Review
- Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies.Pharmaceutical medicine · 2020Article
- Randomized evaluation of trial acceptability by INcentive (RETAIN): Study protocol for two embedded randomized controlled trials.Contemporary clinical trials · 2019Article
- Accelerating anticancer drug development - opportunities and trade-offs.Nature reviews. Clinical oncology · 2018Review
- Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.Clinical and translational science · 2018Review
- Standard of care in immunotherapy trials: Challenges and considerations.Human vaccines & immunotherapeutics · 2017Review
- The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies.Leukemia · 2017Article
- Combination immunotherapy: a road map.Journal for immunotherapy of cancer · 2017Review
- PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.Clinical pharmacology and therapeutics · 2016Article
- Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual.Clinical cancer research : an official journal of the American Association for Cancer Research · 2016Review
- Clinical trials: New drug for pancreatic cancer highlights the dual effect of regulatory approvals.Nature reviews. Clinical oncology · 2016Article
- Cancer immunotherapy trials: leading a paradigm shift in drug development.Journal for immunotherapy of cancer · 2016Article
- Next-Generation Sequencing to Guide Clinical Trials.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The last decade in oncology has been marked by the identification of numerous new potential cancer targets and even more agents designed to inhibit them. The matrix of new targets, new agents, and the companion diagnostics required to identify the right patient for the right drug has created a major challenge for the clinical trial process. This has been compounded by the addition of new immunomodulators targeting the host immune system rather than the tumor. Recognizing the need for new approaches, industry, investigators, and regulators have responded to this challenge. New clinical trial designs are being evaluated to incorporate the genomic sequence data being obtained almost routinely after cancer diagnosis. New dose-finding approaches are being proposed to identify the maximum effective dose rather than the maximum tolerated dose. The FDA is involved in the drug approval process from points early in development and has accepted registration quality data from expansion cohorts in support of drug approval. Despite progress on several fronts, many challenges remain, including the lack of predictability of preclinical data for clinical results and phase II data for phase III results, an infrastructure that can be an obstacle to clinical trial development and implementation, and the increasing use of contracted clinical research organizations that limit a fit-for-purpose approach to clinical trial execution. Perhaps most challenging and important of all are the difficulties with clinical trial accrual that can prevent study completion. Both the innovations and the challenges highlight the important role of process in progress in clinical oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.